.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Find suppliers and generic API sources
  • Predict branded drug patent expiration

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Harvard Business School
Accenture
Express Scripts
Chinese Patent Office
Novartis
Teva
Covington
Julphar
McKesson

Generated: June 27, 2017

DrugPatentWatch Database Preview

MYFORTIC Drug Profile

« Back to Dashboard

What is the patent landscape for Myfortic, and what generic Myfortic alternatives are available?

Myfortic is a drug marketed by Novartis and is included in one NDA. There are three patents protecting this drug and two Paragraph IV challenges.

This drug has fifty-seven patent family members in thirty-eight countries.

The generic ingredient in MYFORTIC is mycophenolic acid. There are sixteen drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the mycophenolic acid profile page.

Summary for Tradename: MYFORTIC

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list80
Clinical Trials: see list96
Patent Applications: see list13,132
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:MYFORTIC at DailyMed

Pharmacology for Tradename: MYFORTIC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
MYFORTIC
mycophenolic acid
TABLET, DELAYED RELEASE;ORAL050791-001Feb 27, 2004ABRXYesNo6,306,900► SubscribeY ► Subscribe
Novartis
MYFORTIC
mycophenolic acid
TABLET, DELAYED RELEASE;ORAL050791-002Feb 27, 2004ABRXYesYes6,306,900► SubscribeY ► Subscribe
Novartis
MYFORTIC
mycophenolic acid
TABLET, DELAYED RELEASE;ORAL050791-001Feb 27, 2004ABRXYesNo6,172,107► SubscribeY ► Subscribe
Novartis
MYFORTIC
mycophenolic acid
TABLET, DELAYED RELEASE;ORAL050791-001Feb 27, 2004ABRXYesNo6,025,391► SubscribeY ► Subscribe
Novartis
MYFORTIC
mycophenolic acid
TABLET, DELAYED RELEASE;ORAL050791-002Feb 27, 2004ABRXYesYes6,025,391► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: MYFORTIC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis
MYFORTIC
mycophenolic acid
TABLET, DELAYED RELEASE;ORAL050791-001Feb 27, 20046,025,391► Subscribe
Novartis
MYFORTIC
mycophenolic acid
TABLET, DELAYED RELEASE;ORAL050791-002Feb 27, 20046,025,391► Subscribe
Novartis
MYFORTIC
mycophenolic acid
TABLET, DELAYED RELEASE;ORAL050791-001Feb 27, 20046,172,107► Subscribe
Novartis
MYFORTIC
mycophenolic acid
TABLET, DELAYED RELEASE;ORAL050791-002Feb 27, 20046,172,107► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: MYFORTIC

Drugname Dosage Strength RLD Submissiondate
mycophenolic acidDelayed-release Tablets180 mgMyfortic6/4/2009
mycophenolic acidDelayed-release Tablets360 mgMyfortic2/2/2009

International Patent Family for Tradename: MYFORTIC

Country Document Number Estimated Expiration
Slovenia892640► Subscribe
United Kingdom9607564► Subscribe
Spain2216141► Subscribe
Argentina006583► Subscribe
Colombia4900024► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: MYFORTIC

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0157Netherlands► Subscribe300157, 20170410, EXPIRES: 20181009
C017/2004Ireland► SubscribeSPC017/2004, 20060201, EXPIRES: 20171023
094Luxembourg► Subscribe91094, EXPIRES: 20181010
C/GB04/030United Kingdom► SubscribeSPC/GB04/030: 20050609, EXPIRES: 20171023
0892640/01Switzerland► SubscribePRODUCT NAME: ACIDUM MYCOPHENOLICUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 56115 24.10.2002
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Covington
QuintilesIMS
Merck
Harvard Business School
McKinsey
Medtronic
UBS
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot